4577 Pharmaceuticals

Elan Corporation plc Period End 31 December 2010

Submitted by Company Reporting on Wed, 2011-11-23 11:39
Elan Corporation plc Annual Report 2010
CR Monitor Issue: 
2011/1109
Company covered: 
Elan Corporation plc
Period End: 
31 December 2010
Report issued on 23 November 2011 covered the following practice issues:
Change
Provision recognised for investigation that was an unquantified contingency in previous period.
Inconsistent
No separate line for share of result of associate on income statement.
Change
Change in segmental disclosure of impairments.
Restatement
Exposure to credit risk restated.

Hikma Pharmaceuticals plc Period End 31 December 2010

Submitted by YWang on Mon, 2011-06-27 12:29
Hikma Pharmaceuticals plc Annual Report 2010
CR Monitor Issue: 
2011/0615
Company covered: 
Hikma Pharmaceuticals plc
Period End: 
31 December 2010
Report issued on 27 June 2011 covered the following practice issues:
Inconsistent
Non-controlling interests that have waived voting rights not recognised.
Change
Acquisition-related costs and gains on revaluation of previously held interest in companies acquired classified as exceptional.
Change
New adjusted earnings per share measure provided.
Change
Depreciation rates on machinery disclosed.
Change
Simplified disclosure for share-based payment transactions.
Change
A previously disclosed dispute resolved to the relevant parties' "mutual satisfaction" but no financial effect indicated.

AstraZeneca plc Period End 31 December 2010

Submitted by Company Reporting on Tue, 2011-05-17 06:30
AstraZeneca plc 2010
CR Monitor Issue: 
2011/0512
Company covered: 
AstraZeneca plc
Period End: 
31 December 2010
Report issued on 17 May 2011 did not identify any changes with significant impacts on the financial statements but covered the following practice issues:
Change
Extended note on financial risk management objectives and policies includes quantification.
Change
A separate analysis of research and development collaboration payments.
Change
Business combination disclosures include pre-acquisition book values and fair value adjustments.

Novo Nordisk A/S Period End 31 December 2010

Submitted by Alisdair on Wed, 2011-04-06 07:43
Novo Nordisk A/S Annual Report 2010
Gain on disposal included in share of profit of associates income statement line item
Danish healthcare company Novo Nordisk includes a DKK1.06 billion gain on disposal of an associate in its income statement line share of profit of associated companies.

Novartis AG Period End 31 December 2010

Submitted by Alisdair on Tue, 2011-03-15 08:07
Novartis Ag Annual report 2010
Share of profit of associates not identified in income statement
Swiss pharmaceutical company Novartis includes in its income statement line item “income from associated companies” a gain arising from remeasuring to fair value its investment prior to obtaining control which results in no separately identified share of profit of associates and therefore falls short of IFRS.